MohammedAsmalMD

Infectious Disease • New York, NY

Venture Partner, OrbiMed Advisers

Join to view full profile

Dr. Asmal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Asmal's full profile

Already have an account?

Office
601 Lexington Ave 54th floor
New York, NY 10022
Phone+1 212-739-6400

Education & Training

Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2006 - 2008
Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003

Certifications & Licensure

MA State Medical License 2005 - 2019

Publications & Presentations

PubMed

42 citations
Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antib...
Mohammed Asmal, Yue Sun, Sophie Lane, Wendy W. Yeh, Stephen D. Schmidt
Journal of Virology. 2011-03-30
63 citations
Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys
Yue Sun, Mohammed Asmal, Sophie Lane, Sallie R. Permar, Stephen D. Schmidt
Journal of Virology. 2011-07-15
29 citations
Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate
Wendy W. Yeh, Pimkwan Jaru-ampornpan, Daiva Nevidomskyte, Mohammed Asmal, Srinivas S. Rao
Journal of Virology. 2009-03-15

Abstracts/Posters

The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
Mohammed Asmal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar Hgb-204 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 PatientsAugust 26th, 2020
Bluebird Bio Announces Topics for Gene Therapy Day, October Investor PresentationOctober 6th, 2016